- Home
- UPXI vs GLMD Comparison
UPXI vs GLMD Comparison
Compare UPXI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- GLMD
- Stock Information
- Founded
- UPXI 2018
- GLMD 2000
- Country
- UPXI United States
- GLMD Israel
- Employees
- UPXI N/A
- GLMD N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- GLMD Health Care
- Exchange
- UPXI Nasdaq
- GLMD Nasdaq
- Market Cap
- UPXI 481.8M
- GLMD 3.0M
- IPO Year
- UPXI 2021
- GLMD 2014
- Fundamental
- Price
- UPXI $10.22
- GLMD $1.25
- Analyst Decision
- UPXI
- GLMD Hold
- Analyst Count
- UPXI 0
- GLMD 1
- Target Price
- UPXI N/A
- GLMD N/A
- AVG Volume (30 Days)
- UPXI 6.7M
- GLMD 4.7M
- Earning Date
- UPXI 05-20-2025
- GLMD 05-29-2025
- Dividend Yield
- UPXI N/A
- GLMD N/A
- EPS Growth
- UPXI N/A
- GLMD N/A
- EPS
- UPXI N/A
- GLMD N/A
- Revenue
- UPXI $18,625,089.00
- GLMD N/A
- Revenue This Year
- UPXI $299.03
- GLMD N/A
- Revenue Next Year
- UPXI N/A
- GLMD N/A
- P/E Ratio
- UPXI N/A
- GLMD N/A
- Revenue Growth
- UPXI 4.75
- GLMD N/A
- 52 Week Low
- UPXI $1.90
- GLMD $1.21
- 52 Week High
- UPXI $22.57
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- UPXI 55.62
- GLMD 40.54
- Support Level
- UPXI $10.69
- GLMD $1.15
- Resistance Level
- UPXI $16.00
- GLMD $1.69
- Average True Range (ATR)
- UPXI 4.05
- GLMD 0.22
- MACD
- UPXI -0.15
- GLMD 0.01
- Stochastic Oscillator
- UPXI 16.95
- GLMD 6.54
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.